Immuron has appointed Pullan Consulting to secure a strategic partner for the global development and commercialisation of its investigational CDI therapy, IMM-529. Following FDA IND 32095 clearance, this initiative aims to accelerate the drug’s Phase II clinical program (NCT03065374).
Written By: Mr Rishabha Sonawane, BPharm
Reviewed By: Pharmacally Editorial Team
Immuron Limited has engaged Pullan Consulting to lead the strategic partnering process for IMM-529, its investigational oral polyclonal antibody therapy for the prevention or treatment of Clostridioides difficile infection (CDI). The initiative follows U.S. Food and Drug Administration authorization of Investigational New Drug (IND) application 32095, enabling the program to advance into a planned Phase II clinical trial (NCT03065374). Through the partnership, Immuron aims to secure a pharmaceutical collaborator to support clinical development through regulatory approval and commercialization of IMM-529.
Pullan Consulting to Lead Licensing and Commercialization Strategy
Pullan Consulting, a life sciences advisory firm with more than 20 years of biotechnology partnering experience, will support Immuron in identifying potential pharmaceutical partners, developing commercialization strategies, negotiating licensing agreements, and executing transactions. Under the proposed licensing model, a partner would typically fund the remaining clinical development, regulatory submissions, manufacturing scale-up, and commercialization activities in exchange for arrangements that may include upfront payments, development and commercial milestones, and royalties on future product sales. Immuron also highlighted historical CDI licensing transactions demonstrating the commercial potential of successful partnership agreements.
Phase II Trial Prepared Following FDA IND Authorization
Beyond receiving FDA authorization, Immuron has completed the Investigator’s Brochure and Phase II clinical protocol, manufactured clinical trial material, appointed a principal investigator, and secured three Australian clinical sites. The study is also eligible to proceed through Australia’s Clinical Trial Notification (CTN) pathway, an expedited mechanism for initiating clinical trials.
The randomized, double-blind, placebo-controlled Phase II study will enroll up to 60 patients with first-episode or recurrent CDI. Participants will receive IMM-529 plus standard-of-care antibiotics or placebo plus standard of care in a 2:1 ratio. The primary endpoint will evaluate safety and tolerability, while secondary endpoints include disease symptoms, mortality, and recurrence rates.
Multivalent Oral Therapy Designed to Preserve the Gut Microbiome
CDI remains a major healthcare-associated infection, particularly among patients receiving prolonged antibiotic therapy. Although antibiotics are the standard treatment, they disrupt the intestinal microbiota and contribute to recurrent disease in nearly one-quarter of patients, creating demand for therapies that reduce recurrence while preserving microbial balance.
IMM-529 is an orally administered polyclonal antibody therapy derived from hyperimmune bovine colostrum that simultaneously targets toxin B, bacterial spores, and surface layer proteins on vegetative C. difficile cells. The company said this multivalent mechanism may differentiate IMM-529 from conventional antibiotics and single-target monoclonal antibody therapies by facilitating pathogen clearance, supporting microbiome recovery, and reducing recurrence. The therapeutic strategy builds on the clinical validation of toxin B through the FDA-approved monoclonal antibody bezlotoxumab, while extending coverage to multiple virulence factors.
Commercial Opportunity Supports Partnering Efforts
An opportunity assessment by Lumanity projected that, if clinical efficacy is demonstrated and reimbursement supports earlier use in the treatment pathway, IMM-529 could achieve approximately US$400 million in annual revenue. By engaging Pullan Consulting following FDA IND authorization, Immuron is seeking to accelerate development through a strategic partnership while positioning IMM-529 as a potential future treatment option for patients with Clostridioides difficile infection.
Reference
https://clinicaltrials.gov/study/NCT03065374
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
About the Writer
Rishabha Sonawane, B.Pharm (LinkedIn) is healthcare writer with a strong interest in medical writing, regulatory affairs, clinical research, and AI-driven drug discovery. He has completed specialized training from the NIH and ICMR in clinical pharmacology, clinical research, and scientific writing. Passionate about evidence-based healthcare communication, he focuses on translating complex scientific research into clear, accurate, and engaging medical content.